Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2022)

Alnylam Pharmaceuticals' Non-Current Debt history runs 7 years deep, the most recent figure standing at $677.7 million for Q2 2022.

• Quarterly Non-Current Debt rose 56.46% year-over-year to $677.7 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $677.7 million (up 56.46% YoY) and the FY2021 annual result came in at $675.7 million, up 253.25% from the prior year.
• Non-Current Debt was $677.7 million for Q2 2022 at Alnylam Pharmaceuticals, roughly flat from $676.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $677.7 million in Q2 2022 and bottomed at $30.0 million in Q1 2018.
• A 5-year average of $266.1 million and a median of $191.3 million in 2020 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2018 — Non-Current Debt sank 80.0% — and 2021, when it surged 253.25%.
• Alnylam Pharmaceuticals' Non-Current Debt stood at $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then soared by 537.59% to $191.3 million in 2020, then jumped by 253.25% to $675.7 million in 2021, then gained by 0.3% to $677.7 million in 2022.
• Business Quant data shows ALNY's Non-Current Debt at $677.7 million in Q2 2022, $676.7 million in Q1 2022, and $675.7 million in Q4 2021.